{"title": "Clinical Trial Finder", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2004-01-01", "cleaned_text": "The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity. | Accepts Healthy Volunteers | Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |No| | Study Type | An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |Interventional| |Eligible Ages||16 Years and Over| |Gender||All| | Trial ID: | This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. | | Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. The person who is responsible for the scientific and technical direction of the entire clinical study. Category of organization(s) involved as sponsor (and collaborator) supporting the trial. The disease, disorder, syndrome, illness, or injury that is being studied. Experimental: Dapirolizumab pegol Subjects will receive dapriolizumab pegol througout the Treatment Period. Placebo Comparator: Placebo Subjects will receive placebo througout the Treatment Period. Drug: - DZP Subjects will receive dapirolizumab pegol at prespecified time-points. Other: - Placebo Subjects will receive placebo at prespecified time-points. If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to [our terms of service](#disclaimer) below. Status Address Sl0043 50140 Birmingham, Alabama, 35205 Status Sl0043 50052 85032 Status 50328 Tucson, 85704 Status Address 50383 Beverly Hills, California, 90211 Status Address Sl0043 50257 Jolla, California, 92037 Status Status California, 90022 Status 92868 Status Status California, 94578 80230 Status Address 50367 New Haven, Connecticut, 06519 Status Address Sl0043 50341 Washington, District of Columbia, 20060 Status Address Sl0043 50239 Brandon, Florida, 33511 Status 50362 32610 Status Status 32174 33324 Status 50329 33606 Status 50283 33613 Status 50368 30303 Status 50382 Atlanta, 30309 Status Address 50240 Idaho Idaho, 83404 Status Sl0043 50310 Illinois, 60612 Status Status Status Address 50333 Grand Blanc, Michigan, 48439 Status Address Sl0043 50273 Las Vegas, Nevada, 89128 Status Address Sl0043 50010 Brooklyn, New York, 11201 Status Address Sl0043 50366 Canton, New York, 13617 Status Address Sl0043 50266 Great Neck, New York, 11021 Status Address Sl0043 50264 Manhasset, New York, 11030 Status Address Sl0043 50077 New York, New York, 10021 Status Address Sl0043 50334 New York, New York, 10032 Status Address Sl0043 50241 Syracuse, New York, 13210 Status Address Sl0043 North Carolina, 28211 Status Carolina, 27157-1010 45242 Status Address 73104 16635 50364 19107 Status 50365 15232 Status 50001 38305 Status 50304 75390 Status 50036 75150 Status 50267 98195 Status Status 25801 Status "}